

GREG WALDEN, OREGON
CHAIRMAN

FRANK PALLONE, JR., NEW JERSEY
RANKING MEMBER

ONE HUNDRED FIFTEENTH CONGRESS
Congress of the United States
House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-2927
Minority (202) 225-3641

November 7, 2017

Ms. Shannon A. Banna
Director of Finance and System Controller
Northside Hospital, Inc.
1000 Johnson Ferry Road, N.E.
Atlanta, GA 30342

Dear Ms. Banna:

Thank you for appearing before the Subcommittee on Oversight and Investigations on Wednesday, October 11, 2017, to testify at the hearing entitled "Examining How Covered Entities Utilize the 340B Drug Pricing Program."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Tuesday, November 21, 2017. Your responses should be mailed to Ali Fulling, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to Ali.Fulling@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Greg Walden
Chairman

cc: The Honorable Diana DeGette, Ranking Member, Subcommittee on Oversight and Investigations

Attachment

Attachment—Additional Questions for the Record

The Honorable Buddy Carter

1. Since 2010, how many independent practices has Northside Hospital acquired?
 - a. What is the practice breakdown for specialties?
 - b. Of those independent practices, how many were specialized in providing oncology services to the community?
2. Since entering the 340B Program in 2013, how many practices and physician sites have you acquired?
 - a. How many of those acquired sites or practices focused on oncology services?
3. In your testimony, you mention that you have 150 ancillary and physician sites located across the 28 county Atlanta Metropolitan Statistical Area. Can you provide a geographic breakdown of those locations?
4. What is the percentage of patient referrals from your ancillary sites that are eligible and utilize drugs covered under the 340B program?
5. How many independent practices have been acquired since 1992?
 - a. How many were acquired between 1992 and 2013?
6. Can you provide your opinion as to why the Disproportionate Share Hospital (DSH) metric, which measures Medicare and Medicaid inpatient stays, is or is not appropriate for use in an outpatient drug program targeting underinsured and uninsured patients?
7. Would you support a new 340B program requirement that mandates a certain level of charity care?
8. Would you support new mandatory reporting/tracking requirements for 340B hospitals to achieve more consistency with respect to program savings?